|
Volumn 43, Issue 6, 2011, Pages 2260-2262
|
Levosimendan for primary graft failure after heart transplantation: A 3-year follow-up
|
Author keywords
[No Author keywords available]
|
Indexed keywords
LEVOSIMENDAN;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
SODIUM;
TACROLIMUS;
ADULT;
ARTICLE;
BODY HEIGHT;
BODY WEIGHT;
CONTINUOUS INFUSION;
CONTROLLED STUDY;
DONOR;
EXTRACORPOREAL OXYGENATION;
FOLLOW UP;
GRAFT FAILURE;
GRAFT RECIPIENT;
GRAFT SURVIVAL;
HEART TRANSPLANTATION;
HUMAN;
ISCHEMIA;
LONG TERM CARE;
MAJOR CLINICAL STUDY;
MORTALITY;
PRIMARY GRAFT FAILURE;
PRIORITY JOURNAL;
RETROSPECTIVE STUDY;
RISK FACTOR;
SODIUM BLOOD LEVEL;
SURVIVAL RATE;
TREATMENT OUTCOME;
ADULT;
AGED;
CARDIOTONIC AGENTS;
FEMALE;
GERMANY;
HEART TRANSPLANTATION;
HUMANS;
HYDRAZONES;
INFUSIONS, PARENTERAL;
MALE;
MIDDLE AGED;
PRIMARY GRAFT DYSFUNCTION;
PYRIDAZINES;
RETROSPECTIVE STUDIES;
RISK ASSESSMENT;
RISK FACTORS;
SURVIVAL RATE;
TIME FACTORS;
TREATMENT OUTCOME;
YOUNG ADULT;
|
EID: 80051699380
PISSN: 00411345
EISSN: 18732623
Source Type: Journal
DOI: 10.1016/j.transproceed.2011.05.021 Document Type: Article |
Times cited : (14)
|
References (8)
|